Clinical Trials Logo

Nausea and Vomiting clinical trials

View clinical trials related to Nausea and Vomiting.

Filter by:

NCT ID: NCT00343460 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Start date: April 2006
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiemetic drugs, such as APF530, palonosetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for cancer. It is not yet known whether APF530 is more effective than palonosetron when given together with dexamethasone in preventing nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.

NCT ID: NCT00310063 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy

Start date: April 2005
Phase: N/A
Study type: Interventional

RATIONALE: Using acupressure wrist bands to press and stimulate nerves at an acupressure point on the inside of the wrist may help control nausea and vomiting caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well acupressure works in preventing nausea and vomiting in young cancer patients receiving chemotherapy.

NCT ID: NCT00293384 Completed - Breast Cancer Clinical Trials

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Start date: October 2004
Phase: N/A
Study type: Interventional

RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying how well giving aprepitant together with granisetron and dexamethasone works in preventing nausea and vomiting in patients receiving cyclophosphamide before undergoing an autologous stem cell transplant.

NCT ID: NCT00179348 Completed - Depression Clinical Trials

Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer

Start date: February 8, 2001
Phase: N/A
Study type: Interventional

This clinical trial studies yoga-based rehabilitation in reducing physical and emotional side effects of living with cancer or its treatment. Yoga-based rehabilitation may reduce side effects and improve the quality of life of patients with breast, lung, or colorectal cancer.

NCT ID: NCT00169572 Completed - Nausea and Vomiting Clinical Trials

Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy

Start date: February 2005
Phase: Phase 2
Study type: Interventional

This study was designed to assess the safety and efficacy of an investigational agent administered in addition to a standard anti-emetic regimen for the treatment of chemotherapy induced nausea and vomiting.

NCT ID: NCT00064272 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

IRB 2003-551
Start date: May 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients receiving chemotherapy for cancer. PURPOSE: This randomized phase II trial is studying how well ginger works in reducing or preventing nausea and vomiting in patients who are receiving chemotherapy for cancer.

NCT ID: NCT00020657 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

Start date: July 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.

NCT ID: NCT00006348 Completed - Lymphoma Clinical Trials

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Start date: October 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not caused by cancer therapy.

NCT ID: NCT00005994 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy

Start date: August 2000
Phase: N/A
Study type: Interventional

RATIONALE: Patient education may improve the effectiveness of ondansetron in preventing nausea and vomiting in patients receiving chemotherapy. PURPOSE: This randomized clinical trial is studying how well patient education works in preventing nausea and vomiting in cancer patients receiving chemotherapy.

NCT ID: NCT00004895 Completed - Colorectal Cancer Clinical Trials

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.